Bridgefront Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Bridgefront Capital’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,180	Closed	-$97.3K	–	551
2022 Q4	$97.3K	Buy	+11,180	New	+$119K	0.07%	337

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgefront Capital's PMVP Position: Q1 2023 in Review

Bridgefront Capital sold out of PMV Pharmaceuticals (PMVP) in Q1 2023, closing a stake of 11,180 shares — an estimated $97.3K sold.

Bridgefront Capital first reported a position in PMVP in Q4 2022 and held it in 1 quarter. The position peaked at $97.3K in Q4 2022. 111 funds tracked by Wall St. Rank hold PMVP as of Q1 2023.

Bridgefront Capital reported no remaining PMV Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Bridgefront Capital sold 11,180 PMV Pharmaceuticals shares in Q1 2023, an estimated $97.3K.
Bridgefront Capital first reported a position in PMV Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Bridgefront Capital's PMV Pharmaceuticals position peaked at $97.3K in Q4 2022.
111 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2023.

Based on Bridgefront Capital's 13F filing for Q1 2023, filed 15 May 2023.